Paper39375952
Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.
Na JY and 8 others. Cancer Sci, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. Papers, record 39375952. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39375952
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Antibodies, Bispecific | Major topic |
| Humans | |
| Male | |
| Female | |
| Adult | |
| Middle Aged | |
| Aged | |
| Models, Biological | |
| Body Weight |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Jeju National University | PubMed |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10826130 | Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. | J Pharmacokinet Biopharm | 1999 | https://conductscience.org/library/papers/10826130 | PubMed |
| 2 | 21803743 | DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. | Cancer Res | 2011 | https://conductscience.org/library/papers/21803743 | PubMed |
| 3 | 37573354 | Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. | J Hematol Oncol | 2023 | https://conductscience.org/library/papers/37573354 | PubMed |
| 4 | 39375952 | Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. | Cancer Sci | 2024 | https://conductscience.org/library/papers/39375952 | PubMed |
| 5 | 33383646 | ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33383646 | PubMed |
| 6 | 27049350 | Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. | MAbs | 2016 | https://conductscience.org/library/papers/27049350 | PubMed |
| 7 | 19620385 | Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. | J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19620385 | PubMed |
| 8 | 15863032 | Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. | Cytokine Growth Factor Rev | 2005 | https://conductscience.org/library/papers/15863032 | PubMed |
| 9 | 19649712 | Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. | AAPS J | 2009 | https://conductscience.org/library/papers/19649712 | PubMed |
| 10 | 33593403 | The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/33593403 | PubMed |
| 11 | 29059436 | Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. | J Natl Cancer Inst | 2017 | https://conductscience.org/library/papers/29059436 | PubMed |
| 12 | 18056450 | Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. | Cancer Res | 2007 | https://conductscience.org/library/papers/18056450 | PubMed |
| 13 | 9561839 | Signaling angiogenesis and lymphangiogenesis. | Curr Opin Cell Biol | 1998 | https://conductscience.org/library/papers/9561839 | PubMed |
| 14 | 17627537 | Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. | Curr Pharm Des | 2007 | https://conductscience.org/library/papers/17627537 | PubMed |
| 15 | 20167860 | Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. | Am J Pathol | 2010 | https://conductscience.org/library/papers/20167860 | PubMed |
| 16 | 15916729 | Recombinant approaches to IgG-like bispecific antibodies. | Acta Pharmacol Sin | 2005 | https://conductscience.org/library/papers/15916729 | PubMed |
| 17 | 11245282 | Molecular mechanisms of tumor angiogenesis and tumor progression. | J Neurooncol | 2000 | https://conductscience.org/library/papers/11245282 | PubMed |
| 18 | 19030102 | Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. | PLoS One | 2008 | https://conductscience.org/library/papers/19030102 | PubMed |
| 19 | 21831306 | Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. | Vasc Cell | 2011 | https://conductscience.org/library/papers/21831306 | PubMed |
| 20 | 27110105 | Weight-based dosing in medication use: what should we know? | Patient Prefer Adherence | 2016 | https://conductscience.org/library/papers/27110105 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42756177 | Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42756177 | PubMed |
| 39375952 | Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. | Cancer Sci | 2024 | https://conductscience.org/library/papers/39375952 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DLL4 | 54567 | PubTator's text mining | https://conductscience.org/library/genes/54567 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39375952
GET https://conductscience.org/api/papers/v1/39375952/references?page=2